Whitepaper examines balances for analytical purposes 

European Pharmacopoeia (Ph. Eur.) General Chapter 2.1.7 Balances for Analytical Purposes was published in July 2021. Compliance with this chapter by January 1, 2022 is mandatory for any pharmaceutical company who manufactures in, or exports into, the European market.  

Balances for Analytical Purposes aims to ensure quality control of medicines in European member states. The requirements of Ph. Eur. are similar to United States Pharmacopeia (USP) General Chapter 41. A new white paper “Weighing According to Ph. Eur.” describes the requirements and implications of Chapter 2.1.7 and explains how to ensure compliance. 

This whitepaper explains: 

  • Requirements of Ph. Eur. Chapter 2.1.7 for weighing instruments 
  • Scope of regulations, for quality control and analytical processes 
  • The importance of calibration, including a statement of measurement uncertainty 
  • Which performance checks and criteria are used to assess accuracy and repeatability 
  • How to determine appropriate testing intervals 
  • How to prove compliance with the appropriate documentation and certificates 
  • Make sure that your weighing processes are fully compliant with the new requirements by January 1, 2022 

Download the whitepaper here. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free